NYMOX PHARMACEUTICAL CORP (CIK: 0001018735) EDGAR, Information, Filings... CompaniesBIO.Com

NYMOX PHARMACEUTICAL CORP

Mailing address
9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT, QUEBEC CANADA, A8, H4M 2V2
Phone
1-800-936-9669
State location
A8
State of incorporation
N/A
Fiscal year end
December 31
SIC
2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Filings
N/A

NYMOX PHARMACEUTICAL CORP (CIK: 0001018735) is an American company incorporated in the state of A8. Head office is located at 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT, QUEBEC CANADA, A8, H4M 2V2. Work in the industry 2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES. NYMOX PHARMACEUTICAL CORP is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Robinson James George	0001651844	May-02-2022	director
Averback Paul	0001569706	Oct-29-2018	director, 10 percent owner, officer: CEO
LANHAM RANDALL J	0001278724	Oct-28-2018	director, officer: General Counsel
Danielsen Erik	0001682873	Aug-10-2016	officer: Chief Financial Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by NYMOX PHARMACEUTICAL CORP

Filings	Format	Description	Filed/Effective	File/Film Number
20-F	Document	Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0001640334-24-001383 (34 Act) Size: KB	Aug-29-2024	001-12033 241264937
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-24-001139 (34 Act) Size: KB	Jul-18-2024	001-12033 241124690
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-24-001122 (34 Act) Size: KB	Jul-16-2024	001-12033 241119235
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-24-000763 (34 Act) Size: KB	May-13-2024	001-12033 24939030
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-24-000510 (34 Act) Size: KB	Mar-28-2024	001-12033 24796778
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-002155 (34 Act) Size: KB	Nov-15-2023	001-12033 231408703
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-002040 (34 Act) Size: KB	Nov-09-2023	001-12033 231391444
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-002021 (34 Act) Size: KB	Nov-06-2023	001-12033 231378802
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001964 (34 Act) Size: KB	Oct-26-2023	001-12033 231349958
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001739 (34 Act) Size: KB	Sep-25-2023	001-12033 231275892
25-NSE	Document	Acc-no: 0001354457-23-000656 (34 Act) Size: KB	Sep-08-2023	001-12033
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001653 (34 Act) Size: KB	Aug-29-2023	001-12033 231221714
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001575 (34 Act) Size: KB	Aug-14-2023	001-12033 231169361
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001425 (34 Act) Size: KB	Aug-02-2023	001-12033 231134776
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001389 (34 Act) Size: KB	Jul-31-2023	001-12033 231126446
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001360 (34 Act) Size: KB	Jul-25-2023	001-12033 231108568
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001358 (34 Act) Size: KB	Jul-25-2023	001-12033 231108542
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001265 (34 Act) Size: KB	Jul-12-2023	001-12033 231085252
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001216 (34 Act) Size: KB	Jul-06-2023	001-12033 231071550
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001640334-23-001158 (34 Act) Size: KB	Jun-29-2023	001-12033 231058434

Recent 20 filings. View all NYMOX PHARMACEUTICAL CORP filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

NYMOX PHARMACEUTICAL CORP overview
NYMOX PHARMACEUTICAL CORP job
NYMOX PHARMACEUTICAL CORP stock
NYMOX PHARMACEUTICAL CORP ownership
NYMOX PHARMACEUTICAL CORP CEO
NYMOX PHARMACEUTICAL CORP documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.